Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated (NYSE: DGX) files reports with the U.S. Securities and Exchange Commission that provide formal insight into its operations as a medical laboratories company focused on diagnostic testing and diagnostic information services. On this page, investors can review Quest Diagnostics’ SEC filings alongside AI-powered tools that help explain the content and context of these documents.
Quest Diagnostics uses current reports on Form 8-K to disclose material events such as quarterly financial results and investor presentations. For example, the company has filed 8-Ks to announce results for specific quarters and to furnish presentation materials used at the J.P. Morgan Healthcare Conference, covering topics such as strategy, performance and market developments. These filings give investors structured access to information that the company shares with the market.
In addition to 8-Ks, users can expect to find Quest Diagnostics’ periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain detailed discussions of business segments, risk factors and financial condition. While these specific forms are not reproduced in the provided data, they are standard components of a public company’s SEC reporting and are accessible through this filings page.
The platform enhances these documents with AI-generated summaries that highlight key points, helping users navigate complex language and lengthy sections. For instance, AI tools can surface main themes from a 10-K, summarize quarterly performance from a 10-Q or clarify the significance of information furnished in an 8-K. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly.
Investors interested in governance, capital allocation and executive communications can use this page to monitor Quest Diagnostics’ regulatory disclosures, while AI assistance streamlines the process of reviewing and interpreting the company’s filings.
Quest Diagnostics Incorporated is offering $500,000,000 aggregate principal amount of 5.000% senior notes due June 30, 2036. The notes accrue interest from May 6, 2026, pay semiannually and were priced at 98.751% of principal. Net proceeds are estimated at $490,505,000 and are expected to be used for general corporate purposes, which may include repayment of the $500,000,000 3.45% Senior Notes maturing on June 1, 2026. The notes are senior unsecured, will rank equally with other senior unsecured obligations, and will be issued in book-entry form through DTC. The offering includes customary redemption features, a change-of-control repurchase at 101%, and covenants limiting liens and certain sale-and-leaseback transactions.
Quest Diagnostics Incorporated is offering senior unsecured notes under a preliminary prospectus supplement dated April 27, 2026. The prospectus supplement describes the notes’ general terms including semiannual interest, optional redemption (including a Par Call Date provision), and a Change of Control repurchase right at 101% of principal plus accrued interest. Net proceeds are expected to be used for general corporate purposes and may include repayment of the Company’s $500 million 3.45% Senior Notes due June 1, 2026. The notes will rank equally with Quest Diagnostics’ other senior unsecured obligations and be structurally subordinated to subsidiary indebtedness. The prospectus incorporates by reference the Company’s 2025 Form 10-K risk factors and other filings.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported an acquisition of 108 shares of common stock on April 20, 2026, at $194.698 per share. After this award, he holds 33,376 shares directly.
Footnotes state the transaction represents an award of restricted share units and reflects shares acquired through a dividend reinvestment plan administered by his broker, which he chose to report early rather than on a later Form 5.
Quest Diagnostics senior executive Patrick Plewman, SVP for Diagnostic Services, reported a small acquisition of company common stock. On April 20, 2026, he acquired 49 shares at $194.699 per share through a dividend reinvestment plan administered by his broker.
Following this transaction, Plewman directly holds 15,247 Quest Diagnostics shares. The filing notes that these dividend reinvestment plan shares are eligible for deferred reporting on Form 5 under Rule 16a-6, but he chose to report the acquisition early on this Form 4.
Quest Diagnostics director Vicky B. Gregg increased her direct holdings through a dividend reinvestment plan. On April 20, 2026, she acquired 68 shares of Quest Diagnostics common stock at $194.698 per share via a broker-administered dividend reinvestment program. Following this automatic acquisition, she directly owns 17,172 shares of common stock. The filing notes this dividend reinvestment transaction was eligible for deferred reporting on Form 5, but she chose to report it early on Form 4.
Quest Diagnostics director Robert B. Carter reported a small acquisition of company stock through a dividend reinvestment plan. On April 20, 2026, he acquired 7 shares of common stock at $194.699 per share, bringing his direct holdings to 2,711 shares.
The shares were acquired automatically under a broker-administered dividend reinvestment plan and are eligible for deferred reporting on Form 5 under Rule 16a-6. Carter chose to report this routine transaction early on Form 4.
Quest Diagnostics director Wright Lassiter III reported a small acquisition of company stock through a dividend reinvestment plan. On April 20, 2026, he acquired 6 shares of common stock at $194.699 per share, bringing his direct holdings to 9,063 shares after the transaction. The filing notes this dividend reinvestment transaction is eligible for deferred reporting under Rule 16a-6, but the director chose to report it early on Form 4.
Quest Diagnostics SVP Karthik Kuppusamy reported a small acquisition of 39 shares of common stock at $194.699 per share. The filing describes this as a small acquisition under Rule 16a-6 related to a dividend reinvestment plan. Following the transaction, he holds 13,490 shares directly, plus indirect holdings through a trust and the company’s 401(k) plan.
Quest Diagnostics senior executive Mark E. Delaney reported a small automatic share acquisition. On April 20, 2026, he acquired 37 shares of Quest Diagnostics common stock at $194.696 per share through a dividend reinvestment plan under Rule 16a-6. Following this transaction, he directly holds 11,901 common shares.
Quest Diagnostics grew solidly in early 2026. Net revenues for the quarter ended March 31, 2026 rose to $2,895 million from $2,652 million, driven mainly by its core diagnostic information services business.
DIS revenue increased 9.4% to $2,832 million as requisition volume grew 10.9%, helped by new relationships with Corewell Health and Fresenius Medical Care. Revenue per requisition fell 1.3% due to a higher mix of routine testing, but excluding these contracts it increased about 2.5%.
Net income attributable to Quest Diagnostics rose to $252 million from $220 million, and diluted EPS increased to $2.24 from $1.94. Operating income improved to $399 million from $346 million as cost savings from the Invigorate program helped offset higher compensation and supplies. Operating cash flow was $278 million versus $314 million, reflecting timing of receipts and higher bonus payments. The company invested $114 million in capital expenditures, continued a quarterly dividend of $0.86 per share, and ended the quarter with $393 million of cash and $5.2 billion of long-term debt.